XTX Topco Ltd Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Key Points

• XTX Topco Ltd purchased a new stake in IDEXX Laboratories, acquiring 3,126 shares valued at approximately $1.31 million in the first quarter.
• IDEXX Laboratories reported earnings of $2.96 per share for the last quarter, exceeding analysts' estimates, with a revenue of $998.43 million, up 3.6% from last year.
• Research analysts have given IDEXX Laboratories a consensus rating of "Moderate Buy", with a target price averaging $557.88 per share.

XTX Topco Ltd acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 3,126 shares of the company's stock, valued at approximately $1,313,000.

Several other institutional investors and hedge funds have also made changes to their positions in IDXX. MorganRosel Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 1st quarter worth about $26,000. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $29,000. Colonial Trust Co SC boosted its position in shares of IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after purchasing an additional 30 shares during the period. Finally, Itau Unibanco Holding S.A. boosted its position in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

IDXX traded up $1.23 on Friday, hitting $535.54. 760,497 shares of the company traded hands, compared to its average volume of 518,616. The company has a 50 day moving average of $530.62 and a 200-day moving average of $470.66. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $43.07 billion, a PE ratio of 49.50, a PEG ratio of 3.80 and a beta of 1.49. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $579.47.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.71 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research analyst reports. Stifel Nicolaus upped their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research report on Wednesday, July 2nd. Leerink Partners upped their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. Finally, Morgan Stanley upped their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $557.88.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director directly owned 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.